Design and Evaluation of a Low Hydrogen Bond Donor Count Fragment Screening Set to Aid Hit Generation of PROTACs Intended for Oral Delivery-Reference-Cited by-同舟云学术

Design and Evaluation of a Low Hydrogen Bond Donor Count Fragment Screening Set to Aid Hit Generation of PROTACs Intended for Oral Delivery

Published:2023-05-24 Issue:11 Volume:66 Page:7594-7604
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Whitehurst Benjamin C.¹^ORCID,Bauer Matthias R.¹^ORCID,Edfeldt Fredrik²,Gunnarsson Anders²,Margreitter Christian³^ORCID,Rawlins Philip B.⁴,Storer R. Ian¹

Affiliation:

1. Hit Discovery, Discovery Sciences, R&D, AstraZeneca, Cambridge CB4 0WG, United Kingdom

2. Mechanistic and Structural Biology, Discovery Sciences, R&D, AstraZeneca, Mölndal, Gothenburg 431 50, Sweden

3. Molecular AI, Discovery Sciences, R&D, AstraZeneca, Mölndal, Gothenburg 431 50, Sweden

4. Mechanistic and Structural Biology, Discovery Sciences, R&D, AstraZeneca, Cambridge CB4 0WG, United Kingdom

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Molecular Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.jmedchem.3c00493

Reference49 articles.

1. Protac-Induced Protein Degradation in Drug Discovery: Breaking the Rules or Just Making New Ones?

2. Targeted protein degradation: expanding the toolbox

3. The rise and rise of protein degradation: Opportunities and challenges ahead

4. PROTAC targeted protein degraders: the past is prologue

5. Targeted protein degraders crowd into the clinic

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Hit me with your best shot: Integrated hit discovery for the next generation of drug targets;Drug Discovery Today;2024-10

2. Targeted protein degradation in CNS disorders: a promising route to novel therapeutics?;Frontiers in Molecular Neuroscience;2024-04-15

3. Discovery of CBPD-409 as a Highly Potent, Selective, and Orally Efficacious CBP/p300 PROTAC Degrader for the Treatment of Advanced Prostate Cancer;Journal of Medicinal Chemistry;2024-03-26

4. Discovery of CBPD-268 as an Exceptionally Potent and Orally Efficacious CBP/p300 PROTAC Degrader Capable of Achieving Tumor Regression;Journal of Medicinal Chemistry;2024-03-13

5. Review of the impact of fragment-based drug design on PROTAC degrader discovery;TrAC Trends in Analytical Chemistry;2024-02